INTRODUCTION: Oral anticoagulants (OAs) are significantly more effective than Aspirin in the prevention of cerebrovascular accidents among patients with atrial fibrillation (AF). Several studies, however, showed OAs to be widely underused in these patients. OBJECTIVE: To assess the appropriateness of antithrombotic therapy in an Italian population of AF patients. METHODS: Two hundred and fifty-five consecutive patients affected by nonvalvular AF participated in the study. Data were collected on demographic characteristics, risk factors for stroke, current prophylactic therapy, and perceived or actual risk factors for bleeding. INR levels were measured. Patients were stratified by their risk for stroke (214 at high risk, 21 moderate, 20 low)...
Oral anticoagulation (OAC) is the only treatment that has shown a significant benefit to reduce the ...
Background Current guidelines strongly recommend that oral anticoagulation should be offered to pati...
The landscape of stroke prevention in patients with atrial fibrillation (AF) is rapidly changing aft...
BACKGROUND: We studied the prevalence of atrial fibrillation within a large Italian inpatient popula...
Background Atrial fibrillation (AF) is associated with a high risk of stroke and other thrombo-embol...
© Springer International Publishing Switzerland 2016.Background and Objectives: Atrial fibrillation ...
Objective: An underuse of oral anticoagulants (OAC) in patients with atrial fibrillation (AF) has be...
PURPOSE: Combined oral anticoagulant (OAC) and antiplatelet (AP) therapy is generally discouraged in...
Background: New oral anticoagulant agents (NOACs) are valid alternatives for vitamin K antagonists (...
BACKGROUND: Current guidelines strongly recommend that oral anticoagulation can be offered to patien...
Aims: Although oral anticoagulants (OACs) are effective in preventing stroke in older people with at...
Atrial fibrillation (AF) is the most frequent cardiac arrhythmia, which is associated with an enhanc...
Background/Introduction: The new oral anticoagulants (NOA), dabigratran, rivaroxaban, apixaban and e...
Oral anticoagulation (OAC) is the only treatment that has shown a significant benefit to reduce the ...
Background Current guidelines strongly recommend that oral anticoagulation should be offered to pati...
The landscape of stroke prevention in patients with atrial fibrillation (AF) is rapidly changing aft...
BACKGROUND: We studied the prevalence of atrial fibrillation within a large Italian inpatient popula...
Background Atrial fibrillation (AF) is associated with a high risk of stroke and other thrombo-embol...
© Springer International Publishing Switzerland 2016.Background and Objectives: Atrial fibrillation ...
Objective: An underuse of oral anticoagulants (OAC) in patients with atrial fibrillation (AF) has be...
PURPOSE: Combined oral anticoagulant (OAC) and antiplatelet (AP) therapy is generally discouraged in...
Background: New oral anticoagulant agents (NOACs) are valid alternatives for vitamin K antagonists (...
BACKGROUND: Current guidelines strongly recommend that oral anticoagulation can be offered to patien...
Aims: Although oral anticoagulants (OACs) are effective in preventing stroke in older people with at...
Atrial fibrillation (AF) is the most frequent cardiac arrhythmia, which is associated with an enhanc...
Background/Introduction: The new oral anticoagulants (NOA), dabigratran, rivaroxaban, apixaban and e...
Oral anticoagulation (OAC) is the only treatment that has shown a significant benefit to reduce the ...
Background Current guidelines strongly recommend that oral anticoagulation should be offered to pati...
The landscape of stroke prevention in patients with atrial fibrillation (AF) is rapidly changing aft...